Founded in December 2021, Averoa’s goal is to build, advance and commercialise a strong pipeline of products to meet significant unmet medical needs of patients with kidney or metabolic diseases.
With a patient-centered approach, our mission is to offer patients comprehensive care of their renal diseases, based on effective therapeutic options supported by accurate diagnosis and advanced prognosis tools.
Averoa dedicates its research programs to develop alternative treatment for patients suffering from renal diseases but also developing reliable biomarkers or tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of a patient.
Dr Luc-André Granier
President & CEO -
Medical Director
Sarah Delbaere
Chief Financial Officer
Caroline Roussel-Maupetit
Chief Operating Officer
Mélanie Cardona
Regulatory Affairs Manager
Scott Donald
Business Development Director
Alexandra Guillermin
Pharmaceutical Development Manager
Catherine Thompson
Clinical-Regulatory Advisor
Identify and develop treatments where science can be applied in new ways of treating diseases with high medical needs.
Value-based health care is about putting the patient at the center to produce the best outcomes.
Develop efficient drugs for patients in a smart and quick way.
Science has become a team activity. We recognize its complexity and help innovative drugs reach their next step of development.
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry.
He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.
His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
25 years of experience in finance, administration and logistics in the pharmaceutical sector with both international companies (Ferring, Takeda/Nycomed) and biotechs (Advicenne, Innogenetics). Having joined Advicenne in 2013, she has supported its development from the first fundraising to its IPO on Euronext.
She masters all the tools to develop the most appropriate financial strategy for Averoa, fundraising, IPO, non- dilutive financing. Her knowledge of human resources management but also of supply chain and the implementation of pharmaceutical distribution networks in Europe makes Sarah an essential asset for the project.
25 years of experience in pharmaceutical development of innovative products . Having participated in the creation of 3 biotechnology companies (Advicenne, synt:em, Protein Performance), Caroline brings 25 years of experience in the development of innovative drugs as well as in the management of subcontracting. Caroline is the author of 4 patents, 3 of which have been granted in Europe, US and Japan.
Her cross-disciplinary vision of pharmaceutical and clinical projects, combined with an excellent knowledge of technical and regulatory aspects, allows her to successfully support innovative therapeutic projects from their initiation to the market.
With a strong background in pharmaceutical and regulatory affairs backgrounds, she has experience in biotechnology companies covering medicines pre-registration and registration procedures.
Having participated and led several projects and submissions including two European centralised procedures, Mélanie has experience in every step of a regulatory development such as scientific advice, orphan designations, paediatric investigation plan and pre-submission steps. She has also an excellent global regulatory knowledge and experience in the management of pharmaceutical packaging, writing of regulatory and technical documents, early access programs and quality system management.
With a scientific background in Molecular Biology, and more than 30 years delivering start-up strategies for Biopharma companies including EU pricing and reimbursement through to arranging country supply chain and commercialisation. Highly developed skills through extensive experience of organisational development, change management and commercialisation strategies.
Previous positions have been EU and Global commercial roles covering the full product Lifecyle as well as holding the position of Managing director of Colonis Pharma tasked with delivering geographic expansion plan for EU, South Africa, and Middle East via identification of assets to fuel growth aspirations.
15 years of experience in pharmaceutical development with both international companies (Mylan, Becton Dickinson, Servier) and biotechs (Advicenne, Panntherapi), Alexandra has conducted many drug developments for US and EU markets.
She brings a complete and bold vision on all CMC aspects for development projects: from the formulation initiation to registration dossier for CMC sections. She is also the author of 2 formulation patents.
Experienced international drug development leader with 25 years in the pharma industry (Allergan, Eisai, Schwartz Pharma) and subsequently a successful consultant (co-founder June Pharma Consulting, BlueReg Pharma Consulting).
Catherine has a proven track record in both development strategy and hands-on operational experience which has led to many successful agency negotiations and approvals across a broad spectrum of indications. She has also authored many publications in peer-reviewed journals.
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
